phospho-PLB (Ser16) Polyclonal Antibody, RBITC Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-2984R-RBITC-100uL |
| Product Name | phospho-PLB (Ser16) Polyclonal Antibody, RBITC Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Dog, Cow, Pig, Rabbit |
| Specifications | |
| Conjugation | RBITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic phosphopeptide derived from human Cardiac phospholamban around the phosphorylation site of Ser16 |
| Modification Site | Ser16 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 5350 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | Phospholamban phospho S16; p-Phospholamban phospho S16; p-PLBS16; Cardiac phospholamban; CMD1P; PLB; PLN; PPLA_HUMAN. |
| Background | Defects in PLN are the cause of cardiomyopathy dilated type 1P (CMD1P) . Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.Defects in PLN are the cause of cardiomyopathy familial hypertrophic type 18 (CMH18) . CMH18 is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is phospho-PLB (Ser16) Polyclonal Antibody, RBITC Conjugated (bs-2984R-RBITC) validated for, and at what dilution?
bs-2984R-RBITC is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does phospho-PLB (Ser16) Polyclonal Antibody, RBITC Conjugated (bs-2984R-RBITC) react with?
Tested reactivity: Human, Mouse, Rat. Predicted reactivity (expected from sequence homology but not yet tested): Dog, Cow, Pig, Rabbit.
How should bs-2984R-RBITC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise phospho-PLB (Ser16) Polyclonal Antibody, RBITC Conjugated (bs-2984R-RBITC)?
KLH conjugated synthetic phosphopeptide derived from human Cardiac phospholamban around the phosphorylation site of Ser16
What are the excitation and emission wavelengths of the RBITC conjugate (bs-2984R-RBITC)?
RBITC on bs-2984R-RBITC: excitation / emission 540nm/625nm.